InsidersTradesSigma
Prestige Consumer Healthcare Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Prestige Consumer Healthcare Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Prestige Consumer Healthcare Inc. has published 67 insider filings. Market capitalisation: €2.3bn. The latest transaction was filed on 14 May 2026 (Retenue fiscale). Among the most active insiders: Sacco Christine. Every trade is openly available.
67
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
30Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 4,504 of 25,791 companies
68.4
score / 100
Value73
Quality64
FCF yld10%
Earn yld8.0%
EV/EBITDA10.4x
ROE10%
Gross mgn55%
Net mgn17%
Debt/EBITDA3.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 14 May 2026
Declarations67 total
1,091 shares@ US$55.090.0023% mcap16.9% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-26-061137:0
2,868 shares@ US$56.780.0071% mcap70.3% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-22-061697:0
4,990 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-058059:0
107,916 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-058055:0
12,243 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-058058:0
4,132 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-058057:0
7,331 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-058056:0
658 shares@ US$55.340.0015% mcap21.7% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-22-056938:0
3,099 shares@ US$55.340.0073% mcap11.9% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-22-056942:0
423 shares@ US$55.340.0010% mcap21.2% of flowCommon StockSEC:0001104659-22-056935:0
482 shares@ US$55.340.0011% mcap11.2% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-22-056936:0
1,055 shares@ US$55.340.0025% mcap18.1% of flowCommon StockSEC:0001104659-22-056941:0
355 shares@ US$55.340.0008% mcap20.9% of flowCommon StockSEC:0001104659-22-056940:0
462 shares@ US$54.440.0011% mcap10.7% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-22-056429:0
404 shares@ US$54.440.0009% mcap23.6% of flowCommon StockSEC:0001104659-22-056431:0
446 shares@ US$54.440.0010% mcap22.2% of flowCommon StockSEC:0001104659-22-056428:0
1,150 shares@ US$54.440.0027% mcap19.6% of flowCommon StockSEC:0001104659-22-056432:0
3,000 shares@ US$54.440.0070% mcap11.5% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-22-056433:0
623 shares@ US$54.440.0015% mcap20.4% of flowCommon Stock, par value $0.01 per shareSEC:0001104659-22-056430:0
3,060 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-055767:0
1,989 shares0Common StockSEC:0001104659-22-055770:0
3,182 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-055769:0
6,120 shares0Common StockSEC:0001104659-22-055771:0
16,523 shares0Common Stock, par value $0.01 per shareSEC:0001104659-22-055772:0
2,142 shares0Common StockSEC:0001104659-22-055766:0
25 of 67 declarations
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a United States consumer healthcare company focused on over-the-counter (OTC) health and personal care products. The company was incorporated in Delaware in 1996 and has built its business around established, name-brand consumer franchises rather than around large-scale prescription pharmaceuticals. Its principal executive offices are in Tarrytown, New York, United States. For French, Belgian and Swiss investors, PBH is best viewed as a branded consumer-health platform with a defensive profile, recurring demand characteristics and strong cash-generation potential. Through its wholly owned subsidiaries, Prestige develops, manufactures, markets, sells and distributes a broad portfolio of OTC products across several everyday health categories. Its core brand family includes well-known names such as Dramamine, Fleet, Clear Eyes, Monistat, Nix, Chloraseptic, Debrox, TheraTears, DenTek, Goody’s, BC, Summer’s Eve, Boudreaux’s Butt Paste and Hydralyte. The company’s products address gastrointestinal health, eye care, oral care, skin care, cough and cold, and women’s health, giving it a diversified but still focused portfolio in consumer self-care. Prestige’s commercial footprint is concentrated in North America, where it sells into mass merchandisers, drugstores, food retailers, dollar stores, convenience channels, club stores and e-commerce. The group also has exposure to Australia and certain other international markets. Its competitive position is built on brand equity, distribution breadth, a low-cost operating model and disciplined marketing execution. In practical terms, Prestige competes not as a diversified pharma giant, but as a specialist owner of mature, trusted OTC brands with strong shelf presence and consumer recognition. Recent developments reinforce that strategy. In fiscal 2025 and fiscal 2026, management highlighted record or near-record financial performance, strong free cash flow and ongoing share repurchases. The company also continued a targeted M&A strategy: it completed the acquisition of Pillar5 Pharma in December 2025, expanding its eye-care capabilities, and in May 2026 announced an agreement to acquire LaCorium Health, an Australian therapeutic skin-care leader. Management also noted operational headwinds such as limited supply for Clear Eyes and some shipping disruptions in the Middle East, but overall described the business model as resilient in a difficult consumer environment. As a result, PBH remains a NYSE-listed United States company with a portfolio-driven model, modest geographic diversification, and a strategy centered on brand stewardship, selective acquisitions, and capital allocation discipline.
